<DOC>
	<DOCNO>NCT01443676</DOCNO>
	<brief_summary>The purpose study explore efficacy bevacizumab combine radiotherapy compare radiotherapy alone treatment newly diagnose glioblastoma elderly . - Trial medicinal product</brief_summary>
	<brief_title>Avastin Plus Radiotherapy Elderly Patients With Glioblastoma</brief_title>
	<detailed_description>This randomize ( 2:1 ) , explorative , parallel-group , open-label , phase II trial elderly patient newly diagnose glioblastoma . In control arm , patient receive radiotherapy , experimental arm , patient receive bevacizumab radiotherapy progression . Background : For decade , neurosurgical resection postoperative radiotherapy cornerstone treatment patient glioblastoma . Most chemotherapeutic agent show little activity malignant glioma patient , possible exception nitrosoureas . This change introduction temozolomide , first show active recurrent disease ( Yung et al . 2000 ) recently newly diagnose glioblastoma ( Stupp et al . 2005 , 2009 ) . This EORTC 26981-22981 NCIC CE.3 trial demonstrate increase median survival 12.1 14.6 month 2 year survival rate 10 % 26 % patient receive radiotherapy plus temozolomide compare radiotherapy alone . Notably patient tumor exhibit methylation promoter region O6-methylguanine DNA methyltransferase ( MGMT ) gene show striking benefit temozolomide ( Hegi et al . 2005 ) . Yet , inclusion trial limit patient age 70 , subgroup analysis demonstrate young patient likely derive benefit combine modality treatment old patient . Thus , radiotherapy alone still standard care elderly . The value radiotherapy confirm small randomize trial compare best supportive care versus radiotherapy alone : median survival 29 week radiotherapy compare 16.9 week supportive care ( Keime-Guibert et al . 2007 ) . Based overall shorter survival elderly patient , hypofractionated radiotherapy explore show equieffective patient age 65-70 year ( Roa et al . 2004 ) . Two randomized trial present abstract form Annual Meeting American Society Clinical Oncology June 2010 fail show superiority primary temozolomide chemotherapy alone radiotherapy alone elderly patient ( Malmstrom et al . 2010 , Wick et al . 2010a ) . In fact , German NOA-08 trial even show primary temozolomide alone non-inferior primary radiotherapy alone ( Wick et al . 2010a ) . A concomitant treatment strategy currently evaluate NCIC-EORTC randomized trial . Further , Nordic trial corroborate equieffectiveness accelerate radiotherapy protocol 40 Gy administer 15 fraction versus standard fractionation 30 x 2 Gy . Altogether , clinical data justify exploration new , temozolomide-free first-line treatment strategy glioblastoma . Glioblastomas express high level vascular endothelial growth factor ( VEGF ) highly vascularized tumor . The VEGF antibody , bevacizumab , recently gain approval patient recurrent glioblastoma USA Switzerland 2009 , EU . Its role first-line treatment glioblastoma currently evaluate randomize trial . There limited data safety efficacy bevacizumab elderly patient glioblastoma , although safety profile bevacizumab elderly patient type cancer , e.g. , lung cancer favorable . There ample rationale combine bevacizumab radiotherapy , include induction VEGF radiotherapy concept vascular normalization result increased oxygenation thus sensitivity radiotherapy . Thus , bevacizumab expect inhibit angiogenesis , may also exhibit additive synergistic interaction radiotherapy impair tumor growth . Altogether , study seek explore , use dedicate neuroimaging protocol , possibility bevacizumab enhance effect radiotherapy via process vascular normalization . The purpose study explore efficacy bevacizumab combine radiotherapy compare radiotherapy alone treatment newly diagnose glioblastoma elderly .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : Diagnosis : newly diagnose glioblastoma elderly patient 1 . Signed informed consent 2 . Age &gt; 65 year 3 . Newly diagnose supratentorial glioblastoma 4 . Eligible first infusion bevacizumab &gt; 28 &gt; 49 day surgery glioblastoma 5 . Karnofsky performance score 60 6 . Paraffinembedded tissue central pathology review 7 . Stable decrease corticosteroid dose within 5 day prior enrolment 8 . Adequate haematological function : 9 . Adequate liver function 10 . Adequate renal function Exclusion criterion : 1 . Karnofsky performance score 50 less 2 . Evidence recent hemorrhage postoperative brain MRI 3 . Tumor infiltration retina , optic nerve , optic chiasm brainstem 4 . Any prior chemotherapy include carmustinecontaining wafer ( GliadelÂ® ) immunotherapy glioblastoma low grade astrocytomas 5 . Any prior radiotherapy brain prior radiotherapy result potential overlap radiation field 6 . Inadequately controlled hypertension 7 . History hypertensive crisis hypertensive encephalopathy 8 . New York Heart Association ( NYHA ) grade II higher congestive heart failure 9 . Myocardial infarction unstable angina within 6 month prior enrolment 10 . Stroke transitory ischemic attack within 6 month prior enrolment 11 . Other significant vascular disease within 6 month prior enrolment 12 . History = grade 2 haemoptysis within 1 month prior enrolment 13 . Bleeding diathesis coagulopathy absence therapeutic anticoagulation 14 . Major surgical procedure , open biopsy , intracranial biopsy , ventriculoperitoneal shunt significant traumatic injury within 28 day prior first dose bevacizumab 15 . Core biopsy ( exclude intracranial biopsy ) minor surgical procedure within 7 day prior first dose bevacizumab 16 . Abdominal fistula gastrointestinal perforation within 6 month prior enrolment 17 . Intracranial abscess within 6 month prior enrolment 18 . Serious nonhealing wound , active ulcer untreated bone fracture 19 . Pregnancy lactation 20 . Fertile woman &lt; 2 year last menstruation men unwilling unable use effective mean contraception 21 . Active malignancy may interfere study treatment investigator ? PI discretion</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>